An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
The use of synthetic organisms could provide opportunities for discovery and advanced manufacturing of medical drugs. Here the authors use a semi-synthetic organism with an expanded genetic code to generate site-specific chemical modifications in human IL-2.
Main Authors: | Jerod L. Ptacin, Carolina E. Caffaro, Lina Ma, Kristine M. San Jose Gall, Hans R. Aerni, Nicole V. Acuff, Rob W. Herman, Yelena Pavlova, Michael J. Pena, David B. Chen, Lilia K. Koriazova, Laura K. Shawver, Ingrid B. Joseph, Marcos E. Milla |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-24987-9 |
Similar Items
-
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism
by: Jerod L. Ptacin, et al.
Published: (2024-03-01) -
Reprogramming cells with synthetic proteins
by: Xiaoxiao Yang, et al.
Published: (2015-06-01) -
Reprogramming Synthetic Cells for Targeted Cancer Therapy
by: Lim, B, et al.
Published: (2022) -
Engineering cell fate: Applying synthetic biology to cellular reprogramming
by: Wang, Nathan B, et al.
Published: (2021) -
Engineering cell fate: Applying synthetic biology to cellular reprogramming
by: Wang, Nathan B, et al.
Published: (2022)